Sensydia
Sensydia Corporation is a Los Angeles–area medical technology company that develops the Cardiac Performance System (CPS), a portable, AI-driven platform combining proprietary acoustic sensors and machine learning to deliver non-invasive hemodynamic measurements (Ejection Fraction, Cardiac Output, Pulmonary Artery Pressure) for hospitals, cardiology offices, and critical care settings.
- Company typePrivate
- Founded2015
- HeadquartersLos Angeles, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Sensydia does
Sensydia Corporation is a privately held medical technology company founded in 2015 and headquartered in Valencia, California (Los Angeles area), operating with 1–10 employees. The company develops the Cardiac Performance System (CPS), a portable, point-of-care platform that combines proprietary broad-band acoustic sensors and ECG biosensors with proprietary waveform machine learning algorithms to deliver non-invasive hemodynamic measurements — Ejection Fraction (EF), Cardiac Output (CO), and Pulmonary Artery Pressure (PAP) — that the company positions as accuracy-equivalent to gold-standard invasive right heart catheterization. The system captures heart sounds and electrical signals, processes them via ML models trained against catheterization lab data, and transmits results via WiFi or Bluetooth to a tablet or cloud in real time, enabling measurement in under five minutes by non-specialist operators across ICU, ER, cardiology office, clinic, and home settings.
The CPS device received FDA 510(k) clearance for Ejection Fraction measurement in 2018 and FDA Breakthrough Device Designation in 2022; the company is currently conducting a multi-center pivotal clinical study (first site enrolled April 2025 at Huntsville Hospital Heart Center) to support FDA submission for expanded CO and PAP indications. Sensydia is also the industry-first beneficiary of AMA Category III CPT code 1036T (published December 2025, effective July 2026), which establishes a dedicated reimbursement pathway for noninvasive augmentative AI hemodynamic assessment. The company is led by CEO Anthony Arnold (ex-Boston Scientific, ex-Medtronic), President & COO Rusty Page (ex-Neuronetics, founding team at Bioness), CTO William Kaiser (UCLA Distinguished Professor of Electrical and Computer Engineering), and CMO Dr. Aman Mahajan (UPMC Department Chair of Anesthesiology), with former Medtronic Chairman & CEO William Hawkins serving as an advisor.
The business model is anchored on hardware sales of the CPS device to hospitals, cardiology practices, and outpatient clinics, with the new CPT code establishing a recurring reimbursement pathway for clinical services performed using the device. To date, Sensydia has raised approximately $8M in equity (May 2023 round led by Orlando Health Ventures with Colle Capital and Frontier Venture Capital) supplemented by a $3M NIH Fast-Track STTR grant and earlier rounds totaling roughly $9.8M since 2016. Customer relationships currently visible in the data are clinical research partnerships (UCLA, U of Minnesota, OHSU, UPMC, Huntsville Hospital) rather than commercial accounts, reflecting the company's pre-commercial / investigational status.
Sensydia firmographics
Firmographics- Name
- Sensydia
- Legal name
- Sensydia Corporation
- Website
- https://sensydia.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Sensydia Corporation is a Los Angeles–area medical technology company that develops the Cardiac Performance System (CPS), a portable, AI-driven platform combining proprietary acoustic sensors and machine learning to deliver non-invasive hemodynamic measurements (Ejection Fraction, Cardiac Output, Pulmonary Artery Pressure) for hospitals, cardiology offices, and critical care settings.
- Ownership category
- akta.pro rank
Sensydia industry classification
Industry- Product category
- Cardiac Monitoring Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration) (HLACAPAI)
- akta.pro secondary industries
- Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices) (HLACAPAK), Cardiology Telemedicine Platforms (HLALAGAB)
Keywords
Where Sensydia is headquartered
LocationHeadquarters
- HQ city
- Los Angeles
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Sensydia business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- CPS Device Sales: Sale of the Cardiac Performance System hardware device to hospitals, clinics, and medical offices. The company plans to commercialize CPS following FDA approval for additional indications beyond the 2018 EF clearance.
- Reimbursement via CPT Code: With the new AMA Category III CPT code 1036T (effective July 1, 2026), Sensydia will receive reimbursement for non-invasive AI hemodynamic assessment services. This establishes a pathway for sustainable revenue from healthcare providers using CPS.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels5 records
Sensydia product offering
Product offeringCore offering
Sensydia develops and sells the Cardiac Performance System (CPS), a portable, non-invasive hemodynamic measurement platform that uses proprietary broad-band acoustic and ECG biosensors combined with proprietary machine learning algorithms to deliver rapid measurement of Ejection Fraction (EF), Cardiac Output (CO), and Pulmonary Artery Pressure (PAP). The handheld device provides gold-standard-equivalent accuracy in under five minutes at the point of care and transmits results via WiFi or Bluetooth to tablets or the cloud, targeting hospitals, cardiologists, and outpatient medical offices.
Product overview
Sensydia offers a single unified product platform: the Cardiac Performance System (CPS), a non-invasive hemodynamic assessment platform that combines proprietary biosensors (broad-band acoustic and ECG sensors) with AI/machine learning algorithms. The CPS platform delivers multiple cardiac measurements (Ejection Fraction, Cardiac Output, Pulmonary Artery Pressure, Pulmonary Artery Occlusion Pressure) through one automated handheld device, positioned as a replacement for invasive catheterization procedures. The platform uses cloud-based data transmission and is designed for use in hospitals, clinics, and telemedicine settings. The company received FDA 510(k) clearance for Ejection Fraction measurement in 2018 and is pursuing additional FDA clearances for other hemodynamic parameters through an ongoing pivotal clinical study.
Differentiator
Problem solved
Functional benefit
Brands
- Cardiac Performance System (CPS): Non-invasive hemodynamic measurement platform that uses biosensors and AI to assess heart function including Ejection Fraction (EF), Cardiac Output (CO), and Pulmonary Artery Pressure (PAP).
Products and services
- Cardiac Performance System (CPS) Portable, non-invasive hemodynamic measurement platform that uses proprietary broad-band acoustic and ECG biosensors combined with machine learning algorithms to deliver automated measurement of Ejection Fraction (EF), Cardiac Output (CO), Pulmonary Artery Pressure (PAP), and Pulmonary Artery Occlusion Pressure (PAOP) in under five minutes. Results are transmitted via WiFi or Bluetooth to tablets or the cloud for point-of-care use in hospitals, cardiology offices, clinics, and telemedicine settings. FDA 510(k) cleared for EF in 2018; additional hemodynamic parameters under clinical validation for expanded FDA indications.
Quantifiable outcome
- CPS identified patients with elevated mPAP (>35mmHg) with AUC of 0.80 and (>30mmHg) with AUC of 0.77 in clinical study
- +4 more outcomes
Companies that use Sensydia
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles2 records
Sensydia technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature5 records
Sensydia partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core.
- University of Minnesota Medical SchoolcoreClinical research partner conducting 50-subject development study for pulmonary pressure algorithms. Dr. Tamas Alexy served as Principal Investigator. University of Minnesota investigators presented ACC 2025 clinical findings.
- Ronald Reagan UCLA Medical CentercoreClinical study site that contributed to FDA clearance for Sensydia's ejection fraction algorithm.
- OHSU Knight Cardiovascular InstitutecoreClinical study site for cardiac output algorithm development.
- University of Pittsburgh Medical Center (UPMC)coreClinical study site for pulmonary pressure algorithm and general clinical utility studies. Dr. Aman Mahajan serves as Chief Medical Officer of Sensydia and is affiliated with UPMC. Collaborating on NIH grant clinical utility studies.
- Huntsville Hospital Heart CentercoreFirst site enrolled in Sensydia's multi-center pivotal study evaluating CPS accuracy compared to gold-standard invasive right heart catheterization. Dr. James D. Murphy, MD, FACC serving as Principal Investigator.
Scale indicators5 records
Recent moves6 records
Expansion highlights5 records
Sensydia competitors and assessment
Company assessmentEmerging players
- Eko Health: Maker of AI-enabled digital stethoscopes (CORE 500, DUO) with FDA-cleared algorithms for detecting atrial fibrillation, heart murmurs, and low ejection fraction. Adjacent AI-cardiac monitoring competitor focused on the ambulatory and clinic setting.
- iRhythm Technologies: Provides the Zio long-term ambulatory ECG cardiac monitoring patch with AI-based arrhythmia detection. Comparable as a clinically validated, AI-driven ambulatory cardiac monitoring device, although focused on rhythm rather than hemodynamic assessment.
- Caretaker Medical: Develops the Vitalstream continuous non-invasive blood pressure and hemodynamic monitor using a finger-cuff pulse-wave analysis method. Closely adjacent competitor in wireless, non-invasive hemodynamic monitoring for hospital and ambulatory use.
Broad incumbents
- GE HealthCare: Provides integrated ICU and perioperative patient monitoring platforms including the CARESCAPE and Portrait systems, covering ECG, SpO2, and invasive hemodynamic parameters. Incumbent hospital channel competitor with established procurement and EMR integration.
- Edwards Lifesciences: Global leader in hemodynamic monitoring, with the Swan-Ganz pulmonary artery catheter as the gold standard for invasive CO/PAP measurement and the ClearSight/Finapres non-invasive finger-cuff system. Directly competes with Sensydia's target use cases across the hospital hemodynamic monitoring workflow.
- Philips: Offers the IntelliVue and X3/X4 patient monitoring platforms with extensive hemodynamic and ECG modules across ICU, ER, and step-down. Broad incumbent competing for hospital monitoring spend and EHR-integrated bedside data.
- Abbott (CardioMEMS): Abbott's CardioMEMS HF System is an implantable pulmonary artery pressure sensor for remote heart-failure monitoring — a direct alternative in the pulmonary hypertension / heart failure management use case Sensydia addresses, though invasive rather than non-invasive.
Direct peers
- USCOM: USCOM manufactures the USCOM 1A non-invasive Doppler-based cardiac output monitor, used in emergency, ICU, and pediatric care. Competes head-to-head with Sensydia on point-of-care, non-invasive hemodynamic assessment.
- Masimo: A leading patient-monitoring company with non-invasive rainbow SET technology covering SpO2, hemoglobin, and respiration, increasingly expanding into multi-parameter continuous vital-sign monitoring. Competitor for clinical-grade vital signs capture in the same hospital channels Sensydia targets.
- Baxter International (Cheetah Medical): Baxter acquired Cheetah Medical, whose Starling SV / NICOM platform provides non-invasive continuous cardiac output and stroke volume monitoring using bioreactance. Most direct non-invasive hemodynamic competitor to Sensydia's CPS in the ICU and ER.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
Sensydia social profiles
Digital presenceSensydia compliance and trust
Trust signalCompliance2 records
Sensydia financial estimates
Financial estimateRevenue estimate
Valuation estimate
Sensydia leadership team
Management profileNumber of profiles
Profiles5 records
Sensydia funding detail
Funding detailFunding overview
Funding rounds5 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Sensydia M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Sensydia
What does Sensydia do?
Sensydia develops and sells the Cardiac Performance System (CPS), a portable, non-invasive hemodynamic measurement platform that uses proprietary broad-band acoustic and ECG biosensors combined with proprietary machine learning algorithms to deliver rapid measurement of Ejection Fraction (EF), Cardiac Output (CO), and Pulmonary Artery Pressure (PAP). The handheld device provides gold-standard-equivalent accuracy in under five minutes at the point of care and transmits results via WiFi or Bluetooth to tablets or the cloud, targeting hospitals, cardiologists, and outpatient medical offices.
Is Sensydia a public or private company?
Sensydia is a private company. It is classified as venture growth investor backed and is currently operating.
When was Sensydia founded?
Sensydia was founded in 2015. It employs 1 to 10 people.
Where is Sensydia based?
Sensydia is headquartered in Los Angeles, United States, in the North America region.
How does Sensydia make money?
Two revenue lines are on record. CPS Device Sales are the primary driver. The others are reimbursement via CPT Code.
Who are Sensydia's main competitors?
Emerging players on record are Eko Health, iRhythm Technologies and Caretaker Medical. Broad incumbents are GE HealthCare, Edwards Lifesciences, Philips and Abbott (CardioMEMS). Direct peers are USCOM, Masimo and Baxter International (Cheetah Medical).
Does Sensydia have an API?
No public API is recorded for Sensydia.
What industry is Sensydia in?
Sensydia's product category is Cardiac Monitoring Devices. Its primary akta.pro industry code is HLACAPAI, Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration), with a secondary code of HLACAPAK, Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices). Its NAICS code is 334510 and its SIC code is 3845.